Clinical Trials

MONDAY, Dec. 7, 2020 — High blood pressure affects Black adults in the U.S. more than any other group. But studies exploring its impact on them remain scant, an analysis of clinical trials over the past decade shows. The analysis, published Monday in the Journal of the American Heart Association, found that of the 956...

Glioblastoma (GBM) is the most common malignant brain tumor originating in the brain. This study, published in CNS Oncology, analyzes disparities in GBM clinical trials. Due to the prevalence and severity of GBM, gaining an accurate understanding of how the disease impacts the general population is essential. Radiation plus concurrent adjuvant temozolomide remains the standard...

Recruitment and enrollment of diverse participants representative of the general population are essential to gain meaningful insight into novel drug therapies. Oncological studies have been previously noted as lacking gender balance, which can result in skewed clinical trial results. This study, published in the Journal of Clinical Oncology, focuses on drug registration trials in particular,...

The risk of prostate cancer is 75% higher in Black patients compared to white patients. Despite worse outcomes, Black patients are still underrepresented as research participants. A recent study not only found new genetic markets of prostate cancer risk but also identified a risk profile that can be applied across populations, emphasizing the value of...

Low-dose aspirin may help some people curb their risk of developing colon cancer — but not if they wait until age 70 to start, a large, new study suggests. Researchers found that when people began using aspirin in their 50s or 60s, their risk of developing colon cancer after age 70 was trimmed by 20%....

To the ever-growing list of COVID-19’s collateral damage, add one more casualty: cancer research. A new study indicates that during the first wave of the pandemic last spring, the number of newly launched cancer treatment studies cratered by 60%. “In short, the first wave of COVID slowed scientific progress in a health-related area distant from...

Decline in trial launches could have long-term negative impact, authors say The COVID-19 pandemic was associated with a 60 percent decrease in the number of launches of oncology clinical trials of drugs and biologic therapies, according to a research letter published online Jan. 27 in JAMA Network Open. Elizabeth B. Lamont, M.D., from Acorn AI, by...

Despite a well-known racial disparity in prostate cancer outcomes, clinical trials still feature majority-white participants. White men account for only 56.3% of prostate cancer cases. A 2020 analysis of 72 clinical trials between 1987 and 2016 found that only 70% of studies reported data on race, and 96% of all participants in studies that did...

It is well-known that minorities are underrepresented in clinical trials at great expense to their health and safety. However, what is not as well-known is the diversity—or, rather, lack thereof—of those calling the shots. A new quality improvement study by Denby et al. found an upsetting lack of diverse leadership in clinical trials, despite the...